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Summary
This study investigates the long-term angiogenic eﬀects of ANG-1 and VEGF in a swine chronic myocardial
ischemia model. Four-weeks after gradual occlusion of the left circumﬂex coronary artery by ameroid con-
strictor, animals were injected with recombinant adenoviral vectors carrying either human ANG-1 (n=9),
human VEGF165 (n=10) or empty vector (n=7) into the left ventricle free wall supplied by the constricted
artery. Left ventricular perfusion in animals that received AdANG-1 (3.25±0.16 ml/min/g, p<0.05)
recovered robustly 4 weeks after gene transfer while ischemia persisted in the AdVEGF (1.09±0.13 ml/min/
g) and empty vector (1.20±0.03 ml/min/g) groups. Microvascular densities in the left ventricles of animals
that received AdANG-1 (19.61±1.76/0.572 mm2 myocardial tissue, p<0.05) and AdVEGF (18.17±1.43/
0.572 mm2 myocardial tissue, p<0.05) were signiﬁcantly higher than animals that received empty vector
(13.53±0.92/0.572 mm2 myocardial tissue) 12 weeks after gene transfer. ANG-1, but not VEGF, contrib-
uted to enhanced regional perfusion by increasing arteriolar density (1.9±0.4/0.572 mm2 myocardial tissue
vs. 0.7±0.2/0.572 mm2 myocardial tissue, p<0.05) of large-sized (50–100 lm) arterioles. These data dem-
onstrate that gene transfer of ANG-1 and VEGF enhances angiogenesis, but ANG-1 promotes sustained
improvement of ventricular perfusion that expedites recovery of ischemic myocardium via arteriogenesis.
Introduction
Ischemic heart disease is a leading public health
concern in the developed world. Despite maximal
therapy, a proportion of patients with symptoms
of chronic ischemia are refractory to conven-
tional drug treatments or revascularization tech-
niques. Some patients are not amenable to
percutaneous coronary intervention or coronary
artery bypass grafting surgery due to the severe
diﬀused nature of the disease. The symptoms of
angina may be debilitating and severely impair
quality of life.
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Revascularization through therapeutic angio-
genesis has the potential to complement conven-
tional revascularization techniques and may
extend treatment options to patients who fail
conventional methods of myocardial revasculari-
zation. Successful therapeutic angiogenesis has
been reported with vascular endothelial growth
factor (VEGF) and ﬁbroblast growth factor
(FGF) in ischemic animal models [1, 2]. Early
clinical trials in a small number of myocardial
ischemic patients have been encouraging [3–6].
However, recent phase II controlled trials using
VEGF and FGF-2 demonstrated only minimal
clinical beneﬁts with no improvement in myocar-
dial perfusion at follow-up [7, 8]. These results
indicate that myocardial angiogenesis in ischemic
heart may be more complicated than previously
believed and its long-term beneﬁts remain uncer-
tain. Alternative growth factors that target diﬀer-
ent aspects of vascular development may be
needed to enhance therapeutic outcomes of angio-
genesis in chronic ischemia.
Due to their anatomical similarities to the
human cardiovascular system, experiments on
large animal models are warranted to better
understand the mechanisms underlying new blood
vessel formation in ischemic myocardium. Swine
are preferred because they have fewer pre-existing
collaterals in the coronary system [9]. Chronic
myocardial ischemia can be achieved by surgical
implantation and intermittent inﬂation of an
external pneumatic coronary occluder [2, 10], or
by placing an ameroid constrictor around a major
coronary artery, usually the proximal left circum-
ﬂex [1, 11–14]. Ameroid constrictor has been most
widely used to study chronic myocardial ischemia
in porcine model [15, 16]. The constrictor consists
of encased hygroscopic casein that expands when
in contact with ﬂuid, resulting in a gradual
occlusion of the encircled artery. Experimental
protocols typically involve administration of
growth factors 3–4 weeks after implantation of
the constrictor, by which time the casein com-
pressed artery has rendered the myocardium
ischemic. Progressive occlusion is preferred be-
cause of the associated low incidence of major
infarction [14].
Angiopoietin-1 (ANG-1) was ﬁrst identiﬁed
as an agonist ligand for endothelial-speciﬁc TIE-2
tyrosine receptor kinase [17] and followed by
other members of the human angiopoietin family,
ANG-2 and ANG-4 [18]. Despite being poorly
mitogenic, ANG-1 shares some of the pro-angio-
genic characteristics of VEGF. Both factors induce
endothelial sprouting and promote survival of
endothelial cells [19, 20]. Although VEGF has
been considered one of the most potent angiogenic
factors in the early stages of angiogenesis, there is
increasing evidence suggesting ANG-1 also plays a
critical role in early phase angiogenesis [21, 22].
ANG-1, by mediating interaction between endo-
thelial cells and their underlying supporting cells,
has been shown to promote angiogenesis in synergy
with VEGF to form mature vasculature [22, 23].
This interaction may also act to maintain stability
and integrity of the vasculature over a longer term
[24]. Furthermore, ANG-1 is the ﬁrst growth factor
identiﬁed to exhibit a potent anti-permeability
eﬀect on blood vessels. This occurs even in the
presence of strong permeability-inducing factors,
such as VEGF and other inﬂammatory molecules
[25, 26]. It regulates vascular permeability by
modulating junctional complexes between endo-
thelial cells [25] thereby maintaining vascular
integrity. This may in turn improve blood ﬂow
dynamics via normalization of the microcirculation
[27, 28].
Importance of ANG-1 in embryonic heart
development has been well documented [24].
However, the eﬀect of ANG-1 on the revascular-
ization of ischemic myocardium remains poorly
understood. Detailed characterization will aid in
the understanding of subtle and unique roles of
individual angiogenic factors in forming functional
vasculature during myocardial ischemia. In this
study, we investigate if adenoviral-mediated gene
transfer of ANG-1 and VEGF is eﬀective in
stimulating sustained neovascularization by study-
ing their long-term eﬀects on vascular develop-
ment and myocardial perfusion in a swine chronic
ischemia model.
Methods
Replicative-deﬁcient adenoviral vector construction
The replicative-deﬁcient vector AdANG-1,
AdVEGF and empty vector were constructed using
an E1/E3-deleted adenovirus serotype 5 vector
from Microbix Biosystems Inc (Toronto, Ontario,
Canada). The transgene (no transgene for empty
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vector construct) is driven by a human cytomega-
lovirus immediate early promoter/enhancer. The
vectors were propagated and puriﬁed in human
embryonic kidney-293 cells as described [29]. Before
use, concentration of viral particles in the stock was
determined at 260 nm using a spectrophotometer
and infectious titer (PFU, plaque-forming unit)
determined using the limiting dilution method in
293 cells as described [29]. All vectors used were
within particle to infectious titer ratio of below 100.
The potency and functionality of our expressed
recombinant humanANG-1 andVEGF165 proteins
on receptor binding and endothelial cell prolifera-
tion have been described previously [29–31].
Porcine model of chronic myocardial ischemia and
gene transfer using AdANG-1 and AdVEGF
All experimental animals were cared for in accor-
dance with guidelines outlined by institutional
animal care and use committee (IACUC). York-
shire swine (30–35 kg) were tranquilized with
ketamine (20 mg/kg) and atropine sulphate
(0.05 mg/kg), inducted with thiopentone (up to
20 mg/kg or until suﬃcient relaxation), intubated
and maintained with general inhalation anesthesia
with 2% isoﬂuorane. Cefazolin (40 mg/kg) and
Labetalol (1 mg/kg) were given intravenously as
prophylaxis against wound infection and arrhyth-
mia. Buprenorphine (up to 0.1 mg/kg as hydro-
chloride) was given for analgesia. A left anterior
mini-thoracotomy was performed through the
fourth intercostal space and the pericardium was
incised and suspended to reveal the free wall of
the left ventricle. Ameroid constrictor (Research
Instruments SW, Escondido, CA, USA) with
2.0–2.5 mm internal diameter was placed around
the circumﬂex artery (LCx) as proximally as
possible. Four weeks after placement of ameroid
constrictor, a second left thoracotomy was per-
formed and a total of 26 pigs were randomized into
three treatment groups. The animals received 10
intramyocardial injections (100 ul per injection)
totaling 11010 plaque forming unit (PFU) of
recombinant adenoviral vector carrying human
ANG-1 (n=9), human VEGF (n=10) or empty
vector (n=7). The respective vectors were injected
using a 27-gauge needle into the free wall of LCx
territory under direct vision with depth limited to
3–4 mm and the sites suture marked for identiﬁca-
tion. The pericardium and chest were closed,
moisture vapor spray dressing and topical antibi-
otic powder were applied to the incision, and the
animals were allowed to recover. Healthy non-
ischemic animals (n=6) that did not receive ame-
roid constrictors were left untreated as baseline
controls.
Regional blood ﬂow measurement
Four weeks after placement of ameroid constric-
tors, ﬂuorescent microspheres purchased from
Molecular Probes (Eugene, OR, USA) were
administered shortly before vector delivery. Micr-
ospheres administration was repeated at 4 and
12 weeks after gene delivery. Microspheres with
15 um diameter in three distinct spectral range;
yellow–green [cat. no. F-8844], red [cat. no.
F-8842] and scarlet [cat. no. F-8843], were injected
at 2.5105 microspheres/kg body weight at each
time point. At least ﬁve transmural myocardial
tissues around the suture marked sites in the free
wall were digested to recover trapped micro-
spheres. Fluorimetry was performed on the
extracted ﬂuorescent dyes using a Perkin-Elmer
LS-50B spectroﬂuorometer (Boston, MA, USA).
All studied animals were included for analysis and
all samples were processed with identical param-
eter settings and blood ﬂow rate (ml/min/g) was
determined as described by manufacturer.
Coronary angiography
Coronary angiography was performed on repre-
sentative animals (n=3–4) from each experimental
group to conﬁrm occlusion of the left circumﬂex
artery at the end of experiment. A 6-French
Judkins left end-hole diagnostic catheter was
placed in the left main coronary artery. The
contrast medium was injected at a continuous rate
until the entire left coronary system and its
branches were completely opaciﬁed. Cineﬂuoros-
copy was performed in standard right anterior
oblique projection with continuous image acquisi-
tion. Collateral vessels from the left anterior
descending coronary artery or obtuse marginal
branch of the circumﬂex coronary artery, were
quantiﬁed following the grading method described
previously [32] by an interventional cardiologist
that was blinded to the study.
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Immunohistological analysis
Animals were sacriﬁced 12 weeks after treatment
and the hearts were perfusion ﬁxed with ice-cold
4% formaldehyde. Transmural myocardial tissue
blocks of 3 cm 1 cm covering the epicardium to
endocardium were taken from the anterior and
lateral walls of left ventricle. Paraﬃn sections of
5 lm were prepared for immunohistochemical
staining. Sections were digested with 0.05% pro-
tease (Sigma-Aldrich, St. Louis, MO, USA),
quenched with 3% hydrogen peroxide and blocked
in 5% goat serum and stained using anti-von
Willebrand factor (vWF) antibody (DakoCytoma-
tion, Glostrup, Denmark) and anti-smooth muscle
actin (SMA) antibody (clone 1A4, Sigma) for
endothelial and smooth muscle cells, respectively,
and anti-human ANG-1 (USBiological, Swamps-
cott, USA) or anti-human VEGF (NeoMarkers,
Fremont, USA) for overnight at 4 C. This was
followed by incubating the sections with peroxi-
dase-labeled polymer (Dakocytomation) and sig-
nals developed with diaminobenzidine (DAB)
substrate, counterstained with hematoxylin and
mounted in Canadian Balsam.
Morphometric analysis and microvascular density
determination
The extent of neoangiogenesis was quantiﬁed
12 weeks after gene transfer by measuring vascular
density of vWF-stained blood vessels in the
ischemic myocardium. Microvessels with a clearly
identiﬁable lumen with diameter less than 20 lm
that oriented perpendicular were counted as pos-
itively stained vessels [33]. This lumen size was
selected based on ﬁndings that these microvessels
were most responsive to ANG-1 and VEGF
stimulation [34]. Arterioles that stained positive
for a-smooth muscle actin were analyzed and
categorized based on lumen diameter (LD) into
small (20 lm>LD< 50 lm)-and large-sized arte-
rioles (50 lm>LD<100 lm). Average microves-
sel area (lm2/vessel/0.572 mm2 myocardial tissue)
was determined from SMA-stained microvessels
by outlining the smooth muscle layer that sur-
rounding a visible vessel lumen of less than 100 lm
in diameter. Counting of all vessels was restricted
to the myocardium and vessels in the connec-
tive tissues near the pericardium were excluded.
Microscopic images (XY resolution of 13001030
pixels with calibrated scaling of 0.6536 lm/pixel
corresponding to a viewing ﬁeld of 0.572 mm2
myocardial tissue) were acquired with a 10 A-
Plan objective lens (NA=0.25) using a Zeiss
Axiovert 200 M microscope and morphometric
data were analyzed using AxioVision 4.3 software
(Carl Zeiss, Hellbergmoos, Germany). Tissue sec-
tions from all studied animals were sampled for
analysis and random microscopic ﬁelds
(0.572 mm2 myocardial tissue/microscopic ﬁeld)
were examined. The mean number of vWF or SMA
stained vessels from each experimental group was
calculated by averaging the total number of vessels
counted from all the sampled tissues.
Gene expression by RT-PCR
In an independent experiment from the main
study, temporal expression proﬁle of human
ANG-1 and human VEGF was separately exam-
ined by RT-PCR following vector-administration
into pigs (n=3) with myocardial ischemia. The
viral vectors carrying these genes were introduced
into the ischemic ventricular free wall after creation
of the ischemic model as described in the main
study. The animals were sacriﬁced 1, 3 and 4 weeks
following gene transfer. Transmural myocardial
samples from vector-treated ischemic area and
right ventricle (as control) of each pig were excised
and cleaned of fatty tissues in ice-cold PBS. RNA
was isolated from cardiac tissue using TRI
Reagent (Molecular Research Center Inc, Cin-
cinnati, OH, USA) as described. RT-PCR was
performed using Qiagen Onestep RT-PCR Kit
(Valencia, CA, USA) and products ampliﬁed at
94 C, 30 s, 57 C, 60 s 72 C, 60 s for 35 cycles. A
combination of gene-speciﬁc (5¢-CGGTGAA
TATTGGCTGGGGAATGAG-3¢) and vector-
speciﬁc primers (5¢-CCATTATAAGCTGCAA
TAAACAAG-3¢) was used to detect ANG-1
expression. Vector-speciﬁc primers (5¢-GATCCAG
CCTGGGGATCAGTCTTCG-3¢ and 5¢-CCAT
TATAAGCTGCAATAAACAAG-3¢) were used
to detect the human VEGF message.
Statistical analysis
Diﬀerences among treatments were analyzed with
one-way analysis of variance (ANOVA) and
582
Tukey test was carried out for subsequent post-hoc
pairwise comparisons. Results were reported as
mean±standard error of mean (SE). All statistical
tests were performed at the p<0.05 signiﬁcance
level using SPSS statistical analysis software
version 11 (SPSS Inc, Chicago, IL, USA).
Results
Chronic ischemia with total occlusion of left
circumﬂex artery
Angiography conﬁrmed complete occlusion of the
circumﬂex coronary artery of all animals examined
16 weeks post placement of constrictor (Figure 1).
Collaterals were observed in all the hearts exam-
ined regardless of the treatment received. How-
ever, the size of the vessels formed after gene
transfer was too small to permit meaningful
angiographic determination.
Viral-mediated gene transfer evokes minimal
inﬂammation in the injected tissues
Fibrotic tissues were mainly observed in areas
surrounding the occluded left circumﬂex artery
that were in close proximity to the ameroid
constrictor. There were no infarct scars nor any
active inﬂammation in the injected myocardium of
animals that received AdANG-1, AdVEGF or
empty vector (data not shown).
ANG-1, but not VEGF, enhances regional blood
ﬂow in the ischemic myocardium
Animals developed ischemia 4 weeks after arterial
constriction with pre-treatment regional blood
ﬂow (RBF) at rest (mean±SE, ml/min/g) signif-
icantly reduced in animals randomized to receive
either AdANG-1 (1.14±0.10, p<0.005), Ad-
VEGF (1.01±0.08, p<0.001) or empty vector
(1.05±0.04, p<0.001) compared to healthy non-
ischemic (1.56±0.07) animals. The RBF among
the treatment groups was not signiﬁcantly diﬀerent
(p=0.338) before initiation of respective treatment
regimes (Figure 2).
Myocardial perfusion in AdANG-1 group
improved by 4 weeks with left ventricular
RBF (3.25±0.16, p<0.001) recovering signiﬁ-
cantly compared to healthy non-ischemic animals
(1.56±0.07) in a robust angiogenic response.
This angiogenic eﬀect of ANG-1 was sustained
with RBF levels remaining elevated at
12 weeks (2.77±0.28, p<0.05) after gene transfer
(Figure 3). In contrast, ischemia persisted in Ad-
VEGF (1.09±0.13, p<0.05) and empty vector
(1.20±0.03, p<0.05) groups at 4 weeks after treat-
ments. The RBF rates in both groups returned to
levels comparable to healthy non-ischemic animals
by 12 weeks after therapy.
Regional blood ﬂow rates in animals that
received AdVEGF were statistically insigniﬁcant
compared to those that received empty vector at
4 (1.09±0.13 vs. 1.20±0.03, p=0.905) and 12
(1.86±0.69 vs. 1.32±0.04, p=0.715) weeks
after gene delivery. In contrast, ANG-1 therapy
Figure 1. Coronary angiography of ischemic swine showed complete occlusion of the left circumﬂex artery 16 weeks after place-
ment of ameroid constrictor. Collaterals were detectable in all groups regardless of treatment received. Arrows indicated ameroid
constrictors.
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signiﬁcantly improved myocardial perfusion com-
pared to animals that received empty vector at 4
(p<0.001) and 12 (p<0.05) weeks after therapy
(Figure 3).
ANG-1 promotes angiogenesis and enhances
arteriole formation in the ischemic myocardium
Immunohistological analysis of the paraﬃn
sections with anti-von Willebrand factor (vWF)
and anti-smooth muscle actin (SMA) antibodies
revealed neither grossly abnormal vessels nor any
hemangioma-like structures in the tissues exam-
ined. Majority of the vasculature were made up of
vessels with diameter less than 20 lm (Figure 4A).
Left ventricular microvascular densities (vessel/
0.572 mm2 myocardial tissue) based on vWF
staining in animals that received AdANG-1
(19.61±1.76, p<0.05) and AdVEGF (18.17±
1.43, p<0.05) were signiﬁcantly higher than ani-
mals that received empty vector (13.53±0.92) or in
healthy control animals (12.20±1.03) (Figure 4B).
There was no signiﬁcant diﬀerence in the num-
ber (arteriole/0.572 mm2 myocardial tissue) of
small-sized arterioles (20–50 lm diameter) among
all the treatment groups. However, a signiﬁcant
increase in the number of large-sized arterioles (50–
100 lm diameter) was found in the AdANG-1
(1.9±0.4, p<0.05), but not the AdVEGF
(0.7±0.2, p=0.892), treated myocardium com-
pared to empty vector or healthy control group
(Figure 5A and B). In addition, average microves-
sel area (lm2/vessel/0.572 mm2 myocardial tissue)
was increased in the AdANG-1 (329.25±19.56,
p<0.001) treated myocardium, but not the
AdVEGF group (183.97±11.73), when compared
to empty vector (195.01±14.09) or healthy control
(167.18±13.25) group (Figure 5C).
Expression of human-speciﬁc ANG-1 mRNA
and VEGF mRNA was detected in the left
ventricle at 1 and 3 weeks, but not 4 weeks, after
gene delivery (Figure 6). No expression was
detected in the right ventricle at the corresponding
periods. This was conﬁrmed by immunohistolog-
ical staining for ANG-1 and VEGF at 3 weeks
after treatment (Figure 7). The expression of
VEGF and ANG-1 was detected in a punctuated
pattern in the myocardium that was consistent
with localized injections of the respective recombi-
nant vectors.
Discussion
Angiogenic growth factors act by inducing prolif-
eration and migration of endothelial cells during
Figure 3. ANG-1 therapy rescued animals from ischemia with
robust recovery in left ventricular perfusion compared to
AdVEGF and empty vector treated groups. The therapeutic
eﬀect of ANG-1 was sustainable with continuous elevated
ventricular perfusion in the left circumﬂex territory. *p<0.05
vs. healthy control animals, #p<0.001 vs. healthy control ani-
mals.
Figure 2. Animals developed ischemia 4 weeks after arterial
constriction with ameroid constrictor. There was no signiﬁ-
cant diﬀerence in the depressed regional perfusion among ani-
mal groups before initiation of treatment. *p<0.005 vs.
healthy control animals, #p<0.001 vs. healthy control ani-
mals.
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angiogenesis. There is evidence to suggest that
speciﬁc functions unique to individual angiogenic
factors may exist during distinct phases of angio-
genesis. For example, VEGF has been recognized
as a primary initiator of new capillary growth
while FGF was implicated in the formation of
large collaterals or arteriogenesis in later stages of
angiogenesis [35–37]. It is apparent that establish-
ing a fully functional neovasculature is likely to
require temporal and sequential interaction of
several major angiogenic factors in a sustained and
coordinated manner.
The precise onset of angiogenesis during ische-
mia is unknown. However, endothelial prolifera-
tion has been observed as soon as 1 day after the
onset of coronary microembolization in a porcine
Figure 4. ANG-1 and VEGF augmented vascular angiogenesis in the ischemic myocardium. (A) AdANG-1 and AdVEGF treated
myocardium showed enhanced neovascularization with increase von Willebrand factor positive vessels. Arrows indicate positively
stained microvessels. Scale bar: 100 lm. (B) ANG-1 and VEGF signiﬁcantly increased microvascular density in the left ventricle
free wall. Microvascular density was computed based on microvessels with lumen sizes less than 20 lm. *p<0.01 vs. healthy con-
trol animals.
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model [38]. One-week after the beginning of
embolization, capillary growth was mainly in the
form of elongation and thickening of the previ-
ously existing vessels. In the case of the chronic
ischemic model adopted in this study, the pattern
of capillary growth may be diﬀerent from that of
an embolism since the process is gradual and the
coronary artery is not totally occluded until
Figure 6. Transient expression of the exogenous human
ANG-1 and VEGF mRNA was suﬃcient to support angio-
genesis in the ischemic myocardium. (A) ANG-1, (B) VEGF.
Lanes 1–3 represents gene expression 1, 3, and 4 weeks after
gene transfer into the left ventricle. Lane 4 represents control
samples from right ventricle. M: Molecular marker.
Figure 5. Neovascularization in AdANG-1 treated myocardium was sustained by arteriole formation and vessel expansion. (A)
AdANG-1 promoted arteriogenesis in the ischemic myocardium. Arrows indicate alpha-smooth muscle actin positive arterioles.
Scale bar: 50 lm. (B) ANG-1 promoted large-sized arterioles formation that supported stability and integrity of the vasculature.
*p<0.05 vs. healthy control animals, #p<0.005 vs. healthy control animals. LD: Lumen diameter. (C) ANG-1 signiﬁcantly aug-
mented average microvessel area in the ischemic myocardium. #p<0.001 vs. healthy control animals.
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3–4 weeks after constrictor placement [39]. There
may be an attenuated, but sustained low level
angiogenic response during the progressive devel-
opment of ischemia. Expression of VEGF and its
receptors in chronic ischemia is upregulated for at
least 2 weeks, suggesting VEGF/VEGFR system
acts as a major mediator of ischemic myocardial
angiogenesis [33]. Therefore, additional adminis-
tration of appropriate therapeutic agents in this
period is expected to enhance the ongoing angio-
genesis. This is especially relevant since native
ANG-1 expression is scarce in ischemic myocar-
dium [33, 40], gene transfer of ANG-1 during
progressive ischemia period may prove to be
useful. This was demonstrated by signiﬁcant
increased microvascular density in the ischemic
myocardium of the AdANG-1 group in our study.
The comparable vascular density improvement
between AdANG-1 and AdVEGF groups sup-
ports ANG-1’s potency in inducing angiogenesis
(Figure 4B). Furthermore, the eﬀect of our Ad-
ANG-1 treatment was comparable to the com-
bined therapeutic eﬀect of AdVEGF and skeletal
myoblast transplantation on vascular density
enhancement that resulted in improved ventricular
function in a swine infarction model [41].
ANG-1 has been reported to signiﬁcantly
increase arteriolar density and reduce infarct size
leading to improved cardiac performance follow-
ing AMI in rodent models [42, 43]. Furthermore,
ANG-1 has been suggested to enhance hemody-
namics by forming more complex vascular net-
work characterized by mature vessels of increased
luminal size [44, 45]. Consistently, our study
showed ANG-1 augmented microvascular density
with signiﬁcant formation of large-sized arterioles
(50–100 lm) and increased total microvascular area
in the ischemic myocardium (Figure 5B and C).
Animals that received AdANG-1 recovered from
ischemia soon after gene transfer with a robust
angiogenic response that led to enhanced tissue
perfusion, and the eﬀect was sustained for at least
12 weeks following therapy. This is likely the
resultant eﬀect of larger size arterioles formed in
response to ANG-1’s stabilizing or maturating
eﬀect since the smaller size arterioles were insuf-
ﬁcient to improve tissue perfusion in the AdVEGF
or empty vector group (Figure 5B). Furthermore,
intense angiogenic response following ANG-1
administration has been reported in an AMI
model whereby vascular density in treated rats
was more than 60% higher than control animals
[42]. Such robust angiogenic response may be due
in part to augmented angiogenesis contributed by
circulating vascular progenitor cells since mobili-
zation of endothelial progenitor cells and bone
marrow stem cells has been observed in response
to ANG-1 [46].
The reduced RBF levels by 12 weeks may
indicate a homeostatic response of the heart to
continuous elevated blood ﬂow rates induced early
after ANG-1 gene transfer. Our previous studies
showed functional improvement without any del-
eterious eﬀects despite transient supraphysiologi-
cal RBF rates following therapy in a similar swine
model [41]. However, dose-escalating AdANG-1
therapy for a more optimum physiological
response may need to be addressed by additional
studies.
Despite the importance of VEGF in angiogen-
esis, our model showed minimal perfusion resto-
ration in response to VEGF. There was no
signiﬁcant diﬀerence in the RBF rates between
AdVEGF and empty vector groups at both
periods examined, even though their RBF levels
normalized by the end of the experiment. The
Figure 7. Immunohistochemical staining of ANG-1 and VEGF expression in the myocardium 3 weeks following intramyocardial
gene transfer. The punctuated positive brown staining pattern is consistent with localized gene expression. Scale bar: 25 lm.
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bioactivity of our vector produced VEGF has been
previously demonstrated [30, 31]. This indicates
that exogenous VEGF failed to improve ventric-
ular perfusion after gene transfer and it contrib-
uted minimally to the normalizing RBF levels
observed at the end of the experiment. In contrast
to recovery observed in the AdANG-1 group,
AdVEGF administered animals remained ischemic
at 4 weeks after gene transfer (Figure 3). The
recovery of RBF in AdVEGF group to levels
comparable to those of the healthy control animals
12 weeks after gene transfer may be due to native
collateral compensation following prolonged
ischemia. However, such compensation may not
necessary result in recovery of myocardial function
as collateral ﬂow is rarely adequate in compensat-
ing fully for the ﬂow lost to occlusion of the native
epicardial coronary arteries [15, 47].
It is noteworthy that Schwarz et al. [48] failed to
observe signiﬁcant changes in regional blood ﬂow
rates despite increased in vascularity in the in-
farcted rodent myocardium following VEGF
administration. Similar ﬁndings on VEGF were
also reported in canine myocardial ischemic model
and rodent hindlimb ischemic model [49, 50]. It is
probable that nascent vessels induced by VEGF
alone may function sub-optimally due to insuﬃ-
cient vascular expansion and large arteriole forma-
tion as demonstrated by our study (Figure 5B and
C). Alternatively, the augmented VEGF levels soon
after gene transfer may have increased vascular
permeability, leading to tissue edema that impaired
tissue perfusion despite comparable increased in
microvascular density between AdVEGF and Ad-
ANG-1 groups. In fact, ANG-1 has been known to
potentiate the angiogenic response to VEGF [45,
51] while counteracting its eﬀect on vascular
permeability [25]. Furthermore, ANG-1 was found
to enhance perfusion only in the presence of
increased levels of endogenous VEGF while exog-
enous applied VEGF failed to improve collateral
blood ﬂow in the ischemic hypoperfused tissues
[52]. Therefore, vascular characteristics evoked in
response to speciﬁc growth factors may explain the
discrepancy observed between perfusion and vas-
cularity in our VEGF administered group.
Despite transient gene expression, temporal
expression proﬁle of the exogenous ANG-1 and
VEGF in our study was adequate to amplify the
downstream angiogenic cascade as evidence by the
enhanced angiogenesis and augmented arteriole
formation in the myocardium. Controlled expres-
sion of angiogenic growth factors during angio-
genesis is crucial since vasculature induced by
prolonged and uncoordinated VEGF expression
has been found to form hemangiomas that failed
to connect to existing circulation [48, 53, 54]. No
abnormal vascular structures were detected in
both AdANG-1 and AdVEGF administered
groups in our study. This suggests that blood
vessels formed soon after gene transfer were stable
and functional outcome of the angiogenic re-
sponse, particularly in the AdANG-1 group, was
sustainable for at least 12 weeks despite transient
nature of the gene expression.
There was no obvious inﬂammatory response in
the myocardium 12 weeks after gene transfer.
However, the slight improvement in vascularity in
the empty vector group compared to the healthy
animal group suggested that inﬂammation-led
neovascularization might have occurred early fol-
lowing vector administration. Furthermore, eﬀect
of surgical related trauma and associated inﬂam-
mation on angiogenesis cannot be excluded totally.
This study presents for the ﬁrst time a
long-term comparison between ANG-1 and VEGF
on the eﬃcacy of therapeutic angiogenesis in a
porcine model of chronic myocardial ischemia. Our
results provide both anatomical and functional
evidence of augmented neovascularization that
support ANG-1 as a potent angiogenic and arteri-
ogenic inducer in ischemic myocardium. Impor-
tantly, ANG-1, but not VEGF, augmented
neovascularization translated to enhanced perfu-
sion and ischemic recovery. The signiﬁcant
improvement in myocardial perfusion supported
by ANG-1 provides strong evidence of its function-
ality during ischemic neovascularization. Its supe-
riority over VEGF in promoting long-term
functional neovascularization may have clinical
signiﬁcance inpatientswith severe chronic ischemia.
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